Hsbc Holdings PLC Takes $25.34 Million Position in Insulet Corporation $PODD

Hsbc Holdings PLC purchased a new stake in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 165,958 shares of the medical instruments supplier’s stock, valued at approximately $25,341,000.

A number of other institutional investors have also modified their holdings of PODD. BlackRock Inc. bought a new position in Insulet in the second quarter worth about $1,018,582,000. Norges Bank bought a new position in shares of Insulet during the fourth quarter valued at approximately $300,794,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Insulet during the second quarter valued at approximately $60,615,000. Finally, Deutsche Bank AG acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $51,153,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on PODD. Leerink Partners downgraded Insulet from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $247.00 to $145.00 in a report on Thursday, August 6th. Canaccord Genuity Group lowered their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Truist Financial reaffirmed a “hold” rating and issued a $153.00 target price (down from $210.00) on shares of Insulet in a research report on Wednesday, August 5th. Citigroup raised their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, TD Cowen reduced their price target on shares of Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a report on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $195.40.

Insulet Stock Performance

PODD opened at $143.41 on Friday. The business’s 50 day moving average is $154.47 and its 200-day moving average is $181.40. The stock has a market cap of $9.95 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period in the previous year, the firm posted $1.17 earnings per share. The business’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.36% of the stock is owned by insiders.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.